Category: Gynecology · High-Risk HPV & Cervical Screening
Other High-Risk HPV Positive for Years Despite a Healthy Lifestyle: Why It Persists, How Dangerous It Is, and How to Follow Up
AI Overview / Quick Answer (BLUF)
HPV hides in basal cervical cells, never enters the bloodstream and dampens local immune signals, so it can persist despite healthy habits. About 9 in 10 infections clear within 2 years. “Other high-risk” pools 12 types; still positive at the 1-year repeat calls for colposcopy, even with a normal Pap.
repeated positive tests for high-risk HPV that is not type 16 or 18 (reported as “other high-risk”) —
why it persists, how risky it is, and the correct follow-up steps.
If you cannot read your report yet, see
Pap and HPV DNA result decoder: ASC-US, LSIL, HSIL and HPV-positive with a normal Pap.
If this is your first positive, see
HPV positive: what to do next.
If you were negative for years and then positive again, see
HPV Type 58 after years of negatives: viral latency.
And if you also have back or pelvic pain, see
HPV with back or pelvic pain ·
Red flags ·
Follow-up steps ·
FAQ
A real question from an HPV support group: I do everything right, so why will it not clear?
Direct answer: long-lasting infection does not mean your body is weak or that you did something wrong. HPV has built-in ways to hide from local immunity in the cervix.
What matters more than waiting for it to clear is checking that your follow-up is complete — especially colposcopy.
A member of a Thai HPV support group wrote that she has had HPV for many years and it will not clear, even though she exercises, is not stressed and rests well.
Her result is not 16/18, but no extended genotyping was done — it was simply reported as “other high-risk”. She asked how long it will take to clear.
(3) how risk differs between types (4) how to follow up, and when colposcopy is needed (5) what can be treated, and what you can actually do.
Red flags — symptoms that need a prompt gynecology visit, not your next routine appointment
Direct answer: HPV infection itself usually causes no symptoms. If you have bleeding after sex, bleeding between periods or after menopause, persistent abnormal discharge, ongoing pelvic or low-back pain with leg swelling, or a visible growth, see a gynecologist promptly for an examination.
Symptoms to get checked promptly
- Bleeding after sex, even a small amount
- Bleeding between periods or unusual spotting
- Any vaginal bleeding after menopause
- Watery, blood-stained or foul-smelling discharge lasting several weeks
- Persistent pelvic or low-back pain, especially with leg swelling
- A lump, growth or sore you can feel or see in the vagina or vulva
1. Why HPV persists despite a healthy lifestyle: local immune evasion
Direct answer: about 9 in 10 infections become undetectable within roughly 2 years, but the rest can persist even in very healthy people,
because the virus stays inside the cervical lining and hides from immune surveillance. Persistence beyond 1–2 years is the key risk signal for
CIN2 or CIN3 precancer.
of HPV infections were undetectable within 24 months in the ALTS study of 4,504 women (Plummer 2007)
chance of persisting another 6 months, rising from a newly found infection to one already present 18 months or more (Plummer 2007)
of non-progressing infections were no longer detected within 3 years, with similar clearance across types (Demarco 2020)
Sources: Plummer 2007;
Demarco 2020 — population figures, not an individual prediction
Where the virus lives, and why the immune system misses it
- It infects basal cells of the cervical lining and makes very few viral proteins there.
- It has no bloodstream phase and does not burst cells or trigger inflammation, so the body gets almost no alarm signal.
- Its E6 and E7 (and E5) proteins dampen local interferon signalling and antigen presentation, so the immune system may not “see” it (Stanley 2012).
- The virus can go latent below the detection limit and become detectable again — one negative test does not prove it is gone forever.
Factors linked to longer persistence (with evidence)
- Smoking, including secondhand smoke — the main modifiable factor. Ever-smokers kept infections longer (median 10.7 vs 8.5 months) and were less likely to clear them, with a dose response by smoking duration (Giuliano 2002).
- Age over 30 — long-standing infections are more common in older women, and most CIN2+ (66 of 85 cases) arose from infections already present rather than new ones (Rodriguez 2010).
- HPV type — some types persist and progress more (see section 2).
- HIV or immunosuppression, for example after organ transplant or on immune-suppressing drugs.
- Long-term combined oral contraceptive use — a small effect; do not stop on your own, discuss with your clinician.
- New or ongoing exposures, which can introduce new types.
Do exercise, sleep and low stress help?
Exercise, sleep and stress management are good for overall health, but there is no proof they clear HPV faster,
and no medicine or supplement has been proven to clear HPV — see
Six months on a supplement and still HPV-positive: can marketing claims clear the virus?
and Probiotics and vitamins for HPV: the medical facts.
Table: natural clearance versus persistent infection
Summarised from long-term follow-up studies — for understanding the big picture, not predicting an individual outcome.
| Aspect | Natural clearance | Persistent infection |
|---|---|---|
| How common | Most — about 9 in 10 undetectable within roughly 2 years | A minority — but the group that needs close follow-up |
| Time course | Usually clears within months to 1–2 years | Still detected beyond 1–2 years; the longer it lasts, the more likely it keeps lasting |
| Precancer risk | Very low | Clearly higher — persistence is the strongest predictor of CIN2/CIN3 |
| What results show | HPV turns negative on repeat testing | HPV positive again, even when the Pap may still be normal |
| Follow-up | Back to routine screening as your clinician advises | Colposcopy ± biopsy, then management by result |
| What it says about you | Not that you cared for yourself better than others | Not that you are weak or did wrong — only that follow-up rules apply |
2. “Other high-risk” is a pooled result of 12 types: a yearly positive may not be the same virus
Direct answer: on many tests, “other high-risk” pools 12 high-risk types that are not 16 or 18.
Years of positives may be the same type persisting or different types acquired and cleared over time — the pooled test cannot tell.
The 12 types in the “other high-risk” pool
- 31
- 33
- 35
- 39
- 45
- 51
- 52
- 56
- 58
- 59
- 66
- 68
Rose = types with a 7-year CIN3+ risk above 5% in Demarco 2020
Positive every year: the same type or a new one?
Each HPV type behaves as an independent infection (Schiffman 2007).
Someone could carry type 52 in year one, clear it, then acquire type 39 the next year — and a pooled test would still report “other high-risk positive”.
Where available, extended genotyping can show whether it is the same type — but current guidelines still count repeated positives as a “persistent positive” and apply the same follow-up rules.
Risk is not equal across types
Overall this group carries lower risk than HPV 16, but not every type is low risk, and the risk is real when infection persists.
A follow-up study of 11,573 women aged 30–65 (Demarco 2020) found these 7-year risks of CIN3 or worse:
HPV 16 — clearly the highest
HPV 18 and 45, and the 31, 33, 35, 52, 58 group
The 39, 51, 56, 59, 68 group (and 66, generally treated as lower risk in practice)
- 31, 33, 45, 52 and 58 carry higher risk than 35, 39, 51, 56, 59, 66 and 68 overall — although in this study type 35 also fell in the above-5% group.
- Type 45 is not low risk — it groups with type 18 and matters in adenocarcinoma, which a Pap test finds less easily.
- Types 52 and 58 are common in Asia, including Thailand.
- The same study found that how long the infection has persisted mattered more for risk than age.
3. How to follow up: repeat at 1 year, and if still positive, colposcopy even with a normal Pap
Direct answer: under ASCCP 2019 (Perkins 2020), which Thai practice follows closely,
HPV-positive results that are not 16/18 with a normal Pap (NILM) are repeated with HPV or co-testing in 1 year. If still positive at that 1-year repeat, colposcopy is recommended even when the Pap is normal.
HPV-positive with ASC-US or LSIL or worse also goes to colposcopy, and HPV 16/18 positive goes straight to colposcopy.
Anyone positive for several years should ask her gynecologist whether colposcopy (and biopsy if needed) has been done.
These guidelines are driven by risk: using screening data from 1.5 million people, each result combination maps to one of 6 actions, from treatment and colposcopy to 1-year or 3-year surveillance or a 5-year return to routine screening
(Egemen 2020). Colposcopy is recommended when the immediate risk of CIN3 or worse is 4% or higher.
A first HPV-positive result with a normal Pap is usually below that threshold, but a repeat positive at 1 year pushes the risk up to the colposcopy threshold.
Follow-up flow when “other high-risk” HPV is positive
What is colposcopy, and does it hurt?
Colposcopy
is an outpatient exam similar to a pelvic exam. The clinician uses a magnifying scope to look at the cervix, applies dilute acetic acid so abnormal areas stand out,
and takes small biopsies of suspicious areas. Most people feel a brief pinch or cramp, and light bleeding for 1–2 days is common.
Table: this result, what comes next
Simplified from ASCCP 2019 for general readers — your clinician may adjust for age, history, pregnancy and local guidelines.
| Result | Recommended next step | Why |
|---|---|---|
| Other high-risk HPV positive + normal Pap (NILM), first time | Repeat HPV or co-test in 1 year | Immediate risk is below the colposcopy threshold, and most clear on their own |
| Still positive at the 1-year repeat (even with a normal Pap) | Colposcopy ± biopsy | Persistence is the key risk signal, and a Pap can miss lesions |
| HPV positive + ASC-US or LSIL | Colposcopy | Risk already reaches the colposcopy threshold |
| HSIL or ASC-H | Colposcopy ± biopsy; in some cases the clinician may go straight to loop excision | High chance of a high-grade lesion already being present |
| HPV 16 or 18 positive | Colposcopy directly, even with a normal Pap | These two types carry the highest risk |
| Normal colposcopy or biopsy | Surveillance per your clinician, often HPV or co-testing yearly | No lesion yet, but the virus is still there, so monitoring continues |
| Biopsy shows CIN1 | Usually observation without surgery, repeat in 1 year | Most CIN1 regresses on its own |
| Biopsy shows CIN2 or CIN3 | Usually excision by loop (LEEP) or cone | Precancer that should be removed; for CIN2 in young people planning pregnancy, close observation may be offered instead |
For what ASC-US, LSIL and HSIL mean, see the Pap and HPV DNA result decoder and NCI — HPV and Pap test results.
Check your cervical screening gap
HPV positive for years, never had colposcopy, or not sure your follow-up is complete — does this apply to me, and how urgent is it?
Analyze your severity level and receive personalized guidance from our Advisory team.
This score ranks screening gaps and urgency; it does not diagnose disease and does not replace an exam by your gynecologist — for worrying symptoms, see the red-flag section above.
4. Treat the lesion, not the virus: what works and what does not
Direct answer: there is no treatment that clears HPV directly. What gets treated is the lesion the virus causes.
CIN2+ or CIN3 is typically removed by loop excision (LEEP) or cone;
CIN1 is usually observed; and after a normal colposcopy or biopsy, surveillance continues as your clinician advises (often yearly).
CIN1: usually observed
CIN1 is a low-grade lesion that often regresses on its own, so it is usually rechecked in 1 year rather than removed, unless higher-grade results are also present.
CIN2 / CIN3: remove the lesion
Loop excision is an outpatient procedure under local anaesthetic, takes a short time, and provides tissue to confirm the diagnosis. HPV testing is still repeated afterwards as scheduled. For recovery and aftercare, see From CIN 1 to CIN 3: LEEP and self-care.
The 9-valent HPV vaccine: protects against types not yet acquired, does not clear existing infection
The 9-valent HPV vaccine does not clear an infection you already have, but it protects against vaccine types you have not yet acquired.
It is routinely recommended through age 26, and from 27 to 45 by shared decision with your clinician (Meites 2019);
many countries, including Thailand, have approved it up to age 45. Some observational studies suggest vaccination around the time of excision may lower recurrence, but this is not proven
— see HPV vaccine after infection: catch-up and shared decision-making at 27–45.
Table: options when other high-risk HPV persists
Procedure classes and generic terms only, no trade names — the choice depends on colposcopy, biopsy and your gynecologist.
| Option | What it does | When it fits | Clears the virus? | Good to know |
|---|---|---|---|---|
| Surveillance (repeat testing) | Repeat HPV or co-testing on schedule | First HPV positive with a normal Pap, or after a normal colposcopy/biopsy or CIN1 | No — relies on the immune system | If still positive at 1 year, move on to colposcopy rather than repeating tests indefinitely |
| Colposcopy + biopsy | Magnified look for abnormal areas, with small biopsies | Persistent positive at 1 year, ASC-US/LSIL or worse, HPV 16/18 | No — it looks for lesions | Outpatient, mild discomfort; the biopsy result decides the next step |
| Loop excision (LEEP) or cone | Removes the area with a high-grade lesion | CIN2+ or CIN3 | Not directly, though many test negative after the lesion is removed | HPV is retested afterwards; discuss future pregnancy with your clinician |
| 9-valent HPV vaccine | Builds antibodies against the vaccine types | Routinely through 26; 27–45 by shared decision | No — protects only against types not yet acquired | After excision it may lower recurrence (not proven) |
| Supplements / “HPV cure” products | Claim to boost immunity or kill the virus | No medical indication | Not effective — no evidence they clear HPV | Costly, and harmful if they delay colposcopy or repeat testing |
| Stop smoking / avoid secondhand smoke | Reduces tobacco carcinogens that build up in the cervical lining | Everyone who smokes or lives with a smoker | Not directly, but smokers keep HPV longer and clear it less often | The most important modifiable factor — get help through quit-smoking resources or a local cessation clinic |
5. What you can actually do while waiting for results and appointments
Direct answer: stop smoking, keep every appointment, ask whether you have reached the colposcopy threshold, and do not spend money on products that claim to clear HPV — screening plus guideline-based follow-up catches precancer early in the great majority of people.
Checklist you can do yourself
- Stop smoking and avoid secondhand smoke — the main modifiable factor.
- Keep every repeat-test and colposcopy appointment, even when you feel fine.
- Use condoms: they reduce transmission but do not fully prevent it, because HPV spreads through skin-to-skin contact.
- Your partner does not need an HPV test — there is no approved screening test for men, and a partner result would not change your plan (How to tell a partner after a positive HPV result).
- Do not buy products marketed as “HPV-clearing” in place of testing.
- Keep all your yearly reports together so your clinician can see how long you have been positive.
Questions to ask your gynecologist at the next visit
- How many years have I been HPV positive in a row, and have I reached the threshold for colposcopy?
- Have I had colposcopy or a biopsy, and what did it show?
- Is extended genotyping available here, and would it change my plan?
- When is my next test due, and which test (HPV alone or co-testing)?
- Should I have the 9-valent HPV vaccine at my age?
- Who should I contact if I have worrying symptoms before my next appointment?
Frequently asked questions (FAQ)
Why has my HPV not cleared for years when I exercise, avoid stress and sleep well?
It does not mean your body is weak or that you did something wrong. HPV lives in the basal cells of the cervical lining, never enters the bloodstream, does not burst cells or cause inflammation, and its E6 and E7 proteins dampen local interferon signals, so the immune system may not see it. Proven persistence factors are smoking including secondhand smoke, older age, the HPV type, HIV or a weakened immune system, and long-term combined oral contraceptive use. Exercise and sleep are good for health, but there is no proof that they clear HPV faster.
How long does other high-risk HPV take to clear?
Nobody can give an exact date, but about 9 in 10 infections become undetectable within roughly 2 years. In the ALTS study, 91 percent cleared within 24 months. The longer an infection lasts, the more likely it is to keep lasting, rising from 37 percent to 65 percent once it has persisted 18 months or more. Persistence beyond 1 to 2 years is therefore the key risk signal for CIN2 or CIN3 precancer, and the reason to follow up on schedule rather than wait.
Could a yearly other high-risk positive be a new HPV type each time?
Yes. On many tests, other high-risk is a pooled result of 12 types: 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68. Years of positives may be the same type persisting or different types acquired and cleared over time, and the pooled test cannot tell them apart. Extended genotyping, where available, can clarify this. Either way, current guidelines still count it as a persistent positive and use the same follow-up rules.
Is other high-risk HPV less dangerous than HPV 16 or 18?
Overall it carries lower risk than HPV 16, but not every type is low risk, and the risk is real when infection persists. In a study of more than 11,000 women aged 30 to 65, the 7-year risk of CIN3 or worse was about 22 percent for HPV 16, above 5 percent for HPV 18 and 45 and for the 31, 33, 35, 52, 58 group, and below 5 percent for 39, 51, 56, 59 and 68. Type 45 in particular is not low risk and matters in adenocarcinoma.
My Pap is normal but HPV has been positive for years. Do I need colposcopy?
Yes, you should discuss it. Under ASCCP 2019, HPV-positive results that are not 16 or 18 with a normal Pap are repeated in 1 year. If the test is still positive at that 1-year repeat, colposcopy is recommended even when the Pap is normal, because persistence is the key risk signal and a Pap can miss lesions. Anyone positive for several years should ask her gynecologist whether colposcopy or a biopsy has been done. Colposcopy is an outpatient exam that magnifies the cervix, uses dilute acetic acid, and takes small biopsies of suspicious areas.
Is there a medicine or supplement that clears HPV faster?
No. No medicine or supplement has been proven to clear HPV, so products marketed as HPV cures should never replace follow-up testing. What can be treated is the lesion the virus causes, such as CIN2 or CIN3, which can be removed by loop excision. The most useful things you can do yourself are to stop smoking, avoid secondhand smoke, and keep every appointment.
Can I still get the 9-valent HPV vaccine after infection, and what does it do?
Yes, but the vaccine does not clear an infection you already have. It protects against vaccine types you have not yet acquired. It is routinely recommended through age 26, and from 27 to 45 by shared decision with your clinician; many countries, including Thailand, have approved it up to age 45. Some observational studies suggest vaccination around the time of excision may lower recurrence, but this is not proven.
Does my partner need an HPV test?
Generally no. There is no approved HPV screening test for men, and a partner result would not change your follow-up plan. Long-term partners usually already share the virus. Condoms reduce transmission but do not fully prevent it, because HPV spreads through skin-to-skin contact. A positive HPV test cannot show when or from whom it was acquired, so it is not evidence of infidelity.
Scientific mechanism
Why the immune system misses the virus: HPV enters basal keratinocytes through micro-abrasions and replicates as the cells mature towards the surface.
The whole cycle stays within the epithelium — no bloodstream phase, no cell death and no inflammation. The virus also suppresses innate immune signalling, so infected cells do not release type I interferons
and antigen-presenting Langerhans cells are not activated. This “immune ignorance” lets infection persist for months to years
(Stanley 2012;
Stanley 2010).
E6, E7 and E5: these proteins interfere with interferon pathways and reduce MHC class I on the cell surface, so cytotoxic T cells struggle to find infected cells.
In long-standing infection, E6 speeds the breakdown of p53 and E7 inactivates pRb, so cells divide abnormally and accumulate genetic damage, forming precancer —
which Schiffman and colleagues summarise as arising from fewer than 10% of new infections, typically within 5–10 years, with invasive cancer taking many more years or decades
(Schiffman 2007) — which is why guideline-based follow-up breaks the chain in time.
Why duration matters most: the longer an infection lasts, the more likely it keeps lasting (37% to 65% per 6 months) (Plummer 2007),
and CIN3+ risk tracks duration of persistence more than age (Demarco 2020).
That is why ASCCP uses a repeat positive at 1 year as the switch to colposcopy.
Why smoking prolongs infection: tobacco carcinogens concentrate in cervical mucus and smoking reduces antigen-presenting cells in the lining; ever-smokers kept infections longer and cleared them less often, with a dose response by smoking duration
(Giuliano 2002).
Written and reviewed by Asst. Prof. Dr. Norawit Raatpiboon
Academic citations (E-E-A-T)
- Perkins RB et al. 2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors. J Low Genit Tract Dis 2020 (PMID 32243307)
- Egemen D et al. Risk Estimates Supporting the 2019 ASCCP Risk-Based Management Consensus Guidelines. J Low Genit Tract Dis 2020 (PMID 32243308)
- Plummer M et al. A 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion. J Infect Dis 2007 (PMID 17471427)
- Rodriguez AC et al. Longitudinal study of human papillomavirus persistence and cervical intraepithelial neoplasia grade 2/3: critical role of duration of infection. J Natl Cancer Inst 2010 (PMID 20157096)
- Schiffman M et al. Human papillomavirus and cervical cancer. Lancet 2007 (PMID 17826171)
- Demarco M et al. A study of type-specific HPV natural history and implications for contemporary cervical cancer screening programs. EClinicalMedicine 2020 (PMID 32510043)
- Giuliano AR et al. Clearance of oncogenic human papillomavirus (HPV) infection: effect of smoking (United States). Cancer Causes Control 2002 (PMID 12462549)
- Meites E et al. Human Papillomavirus Vaccination for Adults: Updated Recommendations of the Advisory Committee on Immunization Practices. MMWR 2019 (PMID 31415491)
- Stanley MA. Epithelial cell responses to infection with human papillomavirus. Clin Microbiol Rev 2012 (PMID 22491770)
- Stanley M. HPV — immune response to infection and vaccination. Infect Agent Cancer 2010 (PMID 20961432)
- NCI — HPV and Pap test results: next steps · NCI — HPV and cancer · MedlinePlus — Cervical cancer
Medical disclaimer
This article is general education about persistent other high-risk HPV infection, reading results and follow-up guidelines.
It is not a diagnosis, prescription or individual treatment plan — decisions about colposcopy, biopsy, excision or vaccination must be made with the gynecologist who looks after you.
Figures come from population studies, and guidelines may differ slightly between countries and hospitals. If you have any red-flag symptom, such as bleeding after sex or after menopause, see a gynecologist promptly.